Logo image of PACB

PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Fundamental Analysis

NASDAQ:PACB - Nasdaq - US69404D1081 - Common Stock - Currency: USD

1.44  -0.02 (-1.37%)

Premarket: 1.42 -0.02 (-1.39%)

Fundamental Rating

2

Overall PACB gets a fundamental rating of 2 out of 10. We evaluated PACB against 57 industry peers in the Life Sciences Tools & Services industry. PACB may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PACB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PACB had negative earnings in the past year.
PACB had a negative operating cash flow in the past year.
In the past 5 years PACB reported 4 times negative net income.
PACB had negative operating cash flow in 4 of the past 5 years.
PACB Yearly Net Income VS EBIT VS OCF VS FCFPACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

PACB has a Return On Assets of -27.19%. This is in the lower half of the industry: PACB underperforms 73.68% of its industry peers.
PACB has a Return On Equity of -87.01%. This is amonst the worse of the industry: PACB underperforms 82.46% of its industry peers.
Industry RankSector Rank
ROA -27.19%
ROE -87.01%
ROIC N/A
ROA(3y)-14.79%
ROA(5y)-18.82%
ROE(3y)-40.82%
ROE(5y)-53.38%
ROIC(3y)N/A
ROIC(5y)N/A
PACB Yearly ROA, ROE, ROICPACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

With a Gross Margin value of 23.81%, PACB is not doing good in the industry: 77.19% of the companies in the same industry are doing better.
PACB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for PACB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.13%
GM growth 5Y-2.57%
PACB Yearly Profit, Operating, Gross MarginsPACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
PACB has more shares outstanding than it did 1 year ago.
PACB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PACB is higher compared to a year ago.
PACB Yearly Shares OutstandingPACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
PACB Yearly Total Debt VS Total AssetsPACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -1.99, we must say that PACB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.99, PACB is not doing good in the industry: 80.70% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.97 is on the high side and indicates that PACB has dependencies on debt financing.
PACB has a Debt to Equity ratio of 1.97. This is amonst the worse of the industry: PACB underperforms 84.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.97
Debt/FCF N/A
Altman-Z -1.99
ROIC/WACCN/A
WACC5.89%
PACB Yearly LT Debt VS Equity VS FCFPACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 9.74 indicates that PACB has no problem at all paying its short term obligations.
PACB's Current ratio of 9.74 is amongst the best of the industry. PACB outperforms 87.72% of its industry peers.
A Quick Ratio of 8.64 indicates that PACB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.64, PACB belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 8.64
PACB Yearly Current Assets VS Current LiabilitesPACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for PACB have decreased strongly by -14.96% in the last year.
The Revenue has been growing slightly by 2.15% in the past year.
The Revenue has been growing by 20.60% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-14.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.38%
Revenue 1Y (TTM)2.15%
Revenue growth 3Y36.47%
Revenue growth 5Y20.6%
Sales Q2Q%-28.23%

3.2 Future

PACB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.55% yearly.
The Revenue is expected to grow by 13.04% on average over the next years. This is quite good.
EPS Next Y-14.74%
EPS Next 2Y19.53%
EPS Next 3Y15.3%
EPS Next 5Y11.55%
Revenue Next Year-22.02%
Revenue Next 2Y-3.31%
Revenue Next 3Y7.16%
Revenue Next 5Y13.04%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PACB Yearly Revenue VS EstimatesPACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
PACB Yearly EPS VS EstimatesPACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PACB. In the last year negative earnings were reported.
Also next year PACB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PACB Price Earnings VS Forward Price EarningsPACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PACB Per share dataPACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as PACB's earnings are expected to grow with 15.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.53%
EPS Next 3Y15.3%

More info and screens

0

5. Dividend

5.1 Amount

PACB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (2/4/2025, 8:00:02 PM)

Premarket: 1.42 -0.02 (-1.39%)

1.44

-0.02 (-1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-13 2025-02-13/amc
Inst Owners85.81%
Inst Owner Change-0.73%
Ins Owners0.59%
Ins Owner Change-2.33%
Market Cap394.36M
Analysts75.45
Price Target2.88 (100%)
Short Float %24.39%
Short Ratio6.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-82.9%
Min EPS beat(2)-169.73%
Max EPS beat(2)3.93%
EPS beat(4)1
Avg EPS beat(4)-43.9%
Min EPS beat(4)-169.73%
Max EPS beat(4)3.93%
EPS beat(8)3
Avg EPS beat(8)-18.18%
EPS beat(12)4
Avg EPS beat(12)-13.99%
EPS beat(16)7
Avg EPS beat(16)-9.61%
Revenue beat(2)0
Avg Revenue beat(2)-10.12%
Min Revenue beat(2)-13.63%
Max Revenue beat(2)-6.61%
Revenue beat(4)0
Avg Revenue beat(4)-8.04%
Min Revenue beat(4)-13.63%
Max Revenue beat(4)-0.47%
Revenue beat(8)4
Avg Revenue beat(8)1.09%
Revenue beat(12)4
Avg Revenue beat(12)-0.51%
Revenue beat(16)8
Avg Revenue beat(16)0.8%
PT rev (1m)-1.34%
PT rev (3m)-3.08%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)-9%
EPS NY rev (1m)-5.11%
EPS NY rev (3m)-6.72%
Revenue NQ rev (1m)-0.69%
Revenue NQ rev (3m)-23.72%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-6.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.28
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.46
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.63
BVpS1.65
TBVpS-1.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.19%
ROE -87.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.81%
FCFM N/A
ROA(3y)-14.79%
ROA(5y)-18.82%
ROE(3y)-40.82%
ROE(5y)-53.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.13%
GM growth 5Y-2.57%
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.96%
Cap/Sales 3.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 8.64
Altman-Z -1.99
F-Score3
WACC5.89%
ROIC/WACCN/A
Cap/Depr(3y)95.34%
Cap/Depr(5y)68.25%
Cap/Sales(3y)7.38%
Cap/Sales(5y)5.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.38%
EPS Next Y-14.74%
EPS Next 2Y19.53%
EPS Next 3Y15.3%
EPS Next 5Y11.55%
Revenue 1Y (TTM)2.15%
Revenue growth 3Y36.47%
Revenue growth 5Y20.6%
Sales Q2Q%-28.23%
Revenue Next Year-22.02%
Revenue Next 2Y-3.31%
Revenue Next 3Y7.16%
Revenue Next 5Y13.04%
EBIT growth 1Y3.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.18%
EBIT Next 3Y16.22%
EBIT Next 5Y13.5%
FCF growth 1Y3.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.59%
OCF growth 3YN/A
OCF growth 5YN/A